– November 1, 2011
November 1, 2011
View Issues
-
Hot Flash Treatment: 2011
In a randomized, double-blind, placebo-controlled trial, clonidine and venlafaxine both proved superior to placebo in reducing hot flashes in breast cancer patients. The study was insufficiently powered to prove superiority of one drug over the other. However, venlafaxine produced earlier reductions and it appeared clonidine had more sustained effect (i.e., at 12 weeks of treatment). -
Height and Cancer Risk
From a large cohort of women followed prospectively and with an adjunct meta-analysis of existing evaluable studies, a clearly demonstrated, nearly universal (i.e., across tumor types) incremental increase in cancer incidence was observed with advancing height. -
Mammographic Breast Density and Breast Cancer Risk in Postmenopausal Women
A 66-year-old postmenopausal retired teacher went to her primary care physician because she found a lump in her right breast during a routine bath. -
The Risk of Surveillance vs Lymph Node Dissection in Germ Cell Cancer: The Occurrence of Second Malignancy
In an epidemiologic analysis of SEER data, middle-aged patients with early-stage disease who opted for active surveillance rather than retroperitoneal lymph node dissection experienced a greater rate of second malignancy. The investigators speculate that this may relate to increased radiation exposure (multiple CT scans) and a greater likelihood of subsequent chemotherapy use. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
Medication poisonings in children; rosuvastatin vs atorvastatin for atherosclerosis; saw palmetto for prostate symptoms; using atypical antipsychotics for off-label indications in adults; and FDA actions.